ANNOUNCEMENT

THE ANNUAL SCIENTIFIC MEETING
OF INDONESIAN UROLOGICAL
ASSOCIATION (ASMIUA) 2017

IN CONJUNCTION WITH
THE ASIA PACIFIC ASSOCIATION
PEDIATRIC UROLOGIST (APAPU)

Perfecting the Aspects
of Urological Practice

November 8th - 11th, 2017
Royal Ambarrukmo Hotel Yogyakarta

www.asmiua-urologi.or.id
DEAR COLLEAGUES AND FRIENDS,

It is my great pleasure to welcome you to our 40th Annual Scientific Meeting of Indonesian Urological Association (ASMIUA) in conjunction with the 19th Asia Pacific Association of Pediatric Urologist (APAPU) meeting that is held in Yogyakarta, Indonesia on November 8th-11th, 2017.

The main theme of this 40th Annual Scientific Meeting of Indonesian Urological Association (ASMIUA) is Perfecting the Aspects of Urological Practice. There will be various workshop that will be held on the first day of the meeting, which consist of Pediatric Urology, Urological Ultrasound, Urological Malignancies Chemotherapy, Urodynamics, and Minimal Invasive on Urology Workshop. We hope during the meeting there will be sharing of knowledge and experiences from our distinguish expert in the field of Urology thus enhancing the Urological services in Indonesia.

Yogyakarta is a historical city. It is known for its artistic and intellectual heritage, craftsmanship, and classical Javanese fine art and culture. It is the location of the world’s largest Buddhist temple, the Borobudur temple.

I welcome you all to Yogyakarta.

Johan Renaldo
CHAIRMAN

DEAR COLLEAGUES AND FRIENDS,

It is my great pleasure to invite all of you to attend the 19th Annual Congress of Asia-Pacific Association of Pediatric Urologist 2017 (APAPU 2017), which will be held on Jogjakarta, Indonesia at November 8th-11th, 2017.

This year APAPU meeting is held in conjunction with the 40th Annual Scientific Meeting of Indonesian Urological Association (ASMIUA). There will be speakers from around the world, who are the best in their field to share knowledge and experiences with us. We hope we can be partner to bring innovation and collaboration between the APAPU members and countries to set a good practices in pediatric urology in order to bring a better future for the children and their family.

We hope you enjoy your stay at Jogjakarta, one of the historical cities in Indonesia, known for its friendly people, historical building and temples, culture, and delicate food.

Selamat Datang.
Welcome to Jogjakarta.
We look forward to meeting all of you in Jogjakarta.

Best Regards,

Tarmono
CHAIRPERSON
OF 19TH ANNUAL APAPU MEETING.
THE ANNUAL SCIENTIFIC MEETING OF INDONESIAN UROLOGICAL ASSOCIATION (ASMIUA) 2017

GENERAL INFORMATION

VENUE
Royal Ambarrukmo Hotel Yogyakarta

IMPORTANT DATE
Workshop: November 8th, 2017
Symposium: November 9th - 11th, 2017
Medical Exhibition: November 9th - 11th, 2017
Early Bird Registration Deadline: September 15th, 2017
Abstract Submission Deadline: September 30th, 2017
Abstract Change of Presenting Author: October 15th, 2017

SCIENTIFIC PROGRAMME

WORKSHOPS
WORKSHOP ON FUNCTIONAL URODYNAMICS
Date: November 8th, 2017
WORKSHOP ON UROLOGICAL MALIGNANCIES CHEMOTHERAPY
Date: November 8th, 2017
WORKSHOP ON ULTRASONOGRAPHY: UROLOGY ASPECTS
Date: November 8th, 2017
WORKSHOP ON MINIMAL INVASIVE TECHNOLOGIES ON UROLOGY
Date: November 8th, 2017
WORKSHOP ON PEDIATRIC UROLOGY
Date: November 8th, 2017

SYMPOSIUM
Symposium Hypospadias
Symposium Hydroureteronephrosis in Children
Symposium Adolescent Varicocele
Symposium Paediatric Stone Disease
Symposium Paediatric Reconstructive Surgery
Symposium Men’s Health
Symposium Disorders of Sex Development
Symposium Scrotal Abnormalities
Symposium Neurogenic Bladder/Enuresis
Symposium Benign Prostate Hyperplasia
Symposium Urological Oncology (Kidney Tumor)
Symposium Urological Oncology (Prostate Cancer)
### WORKSHOP FUNCTIONAL URODYNAMICS

**Date:** November 8th, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 - 08.10</td>
<td>Opening Remarks</td>
</tr>
<tr>
<td>08.10 - 08.30</td>
<td>Equipment: Choice of Equipment and How to Set It Up</td>
</tr>
<tr>
<td>08.30 - 08.50</td>
<td>Basic Principles and Indications of Urodynamic</td>
</tr>
<tr>
<td>08.50 - 09.10</td>
<td>Types of Urodynamic Tests</td>
</tr>
<tr>
<td>09.10 - 09.20</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>09.20 - 09.30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>09.30 - 09.50</td>
<td>Aspects to Urodynamic Measurement: Pressure, Flow, and EMG</td>
</tr>
<tr>
<td>09.50 - 10.10</td>
<td>Pitfalls and Troubleshooting in Urodynamic</td>
</tr>
<tr>
<td>10.10 - 10.30</td>
<td>Recognition and Correction of Artifacts</td>
</tr>
<tr>
<td>10.30 - 10.50</td>
<td>Video and Ambulatory Urodynamic: Why and When</td>
</tr>
<tr>
<td>10.50 - 11.00</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>11.00 - 11.20</td>
<td>Urodynamic Assessment of Storage/Filling</td>
</tr>
<tr>
<td>11.20 - 11.40</td>
<td>Urodynamic Assessment of Voiding</td>
</tr>
<tr>
<td>11.40 - 12.00</td>
<td>How to Write Urodynamic Report</td>
</tr>
<tr>
<td>12.00 - 12.20</td>
<td>Analysis and Interpretation of Urodynamic Result</td>
</tr>
<tr>
<td>12.20 - 12.30</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>12.30 - 13.00</td>
<td>Lunch</td>
</tr>
<tr>
<td>13.00 - 13.20</td>
<td>Urodynamic Testing in Female LUTS: SUI, UI, and POP</td>
</tr>
<tr>
<td>13.20 - 13.40</td>
<td>Urodynamic Testing in Male LUTS: BOO</td>
</tr>
<tr>
<td>13.40 - 14.00</td>
<td>How to Perform Urodynamic in Children</td>
</tr>
<tr>
<td>14.00 - 14.20</td>
<td>Urethral Pressure Profile: How and When to Perform</td>
</tr>
<tr>
<td>14.20 - 14.30</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>14.30 - 14.40</td>
<td>Coffee Break</td>
</tr>
</tbody>
</table>
WORKSHOP ON UROLOGICAL MALIGNANCIES CHEMOTHERAPY  
Date: November 8th, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 - 08.35</td>
<td>Opening Remarks</td>
</tr>
<tr>
<td>08.35 - 09.05</td>
<td>Role of Urologists in Urological Malignancies Chemotherapy</td>
</tr>
<tr>
<td>09.05 - 09.35</td>
<td>Urological Malignancies Chemotherapy: Multicenter Experiences</td>
</tr>
<tr>
<td>09.35 - 09.50</td>
<td>Coffee Break</td>
</tr>
</tbody>
</table>

**Basic Urological Chemotherapy**

<table>
<thead>
<tr>
<th>Time</th>
<th>Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.50 - 10.20</td>
<td>Chemotherapy in Urological Malignancies: Basic Principles</td>
</tr>
<tr>
<td>10.20 - 10.50</td>
<td>Urological Chemotherapy Regimens: What’s New</td>
</tr>
<tr>
<td>10.50 - 11.10</td>
<td>Premedication for Chemotherapy: When and How to Do It</td>
</tr>
<tr>
<td>11.10 - 11.40</td>
<td>Chemotherapy Side Effects: How to Prevent It</td>
</tr>
<tr>
<td>12.00 - 12.10</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>12.10 - 13.00</td>
<td>Lunch</td>
</tr>
</tbody>
</table>

**Kidney Cancer**

<table>
<thead>
<tr>
<th>Time</th>
<th>Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00 - 13.20</td>
<td>Kidney Cancer Guideline: The Updates</td>
</tr>
<tr>
<td>13.20 - 13.40</td>
<td>Systemic Therapy for Metastatic RCC: What is Our Choices?</td>
</tr>
<tr>
<td>13.40 - 13.55</td>
<td>Management of Locally Advanced Unresectable RCC</td>
</tr>
<tr>
<td>13.55 - 14.00</td>
<td>Q&amp;A</td>
</tr>
</tbody>
</table>

**Bladder Cancer**

<table>
<thead>
<tr>
<th>Time</th>
<th>Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 - 14.20</td>
<td>Recent Update on the Management of Bladder Cancer</td>
</tr>
<tr>
<td>14.20 - 14.40</td>
<td>How to Improving the Efficacy of Intravesical Therapy</td>
</tr>
<tr>
<td>14.40 - 14.55</td>
<td>Treatment of Failure of Intravesical Therapy: What to Do Next</td>
</tr>
<tr>
<td>14.55 - 15.00</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>15.00 - 15.20</td>
<td>Coffee Break</td>
</tr>
</tbody>
</table>

**Prostate Cancer**

<table>
<thead>
<tr>
<th>Time</th>
<th>Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.20 - 15.40</td>
<td>Management of Prostate Cancer: What’s New</td>
</tr>
<tr>
<td>15.40 - 16.00</td>
<td>Management of Bone Metastasis in Prostate Cancer</td>
</tr>
<tr>
<td>16.00 - 16.20</td>
<td>Drug of Choice for Castration Resistant Prostate Cancer</td>
</tr>
<tr>
<td>16.20 - 16.40</td>
<td>The Roles of DRE and PSA in Predicting Prostate Cancer Risk</td>
</tr>
<tr>
<td>16.40 - 16.45</td>
<td>Q &amp; A</td>
</tr>
</tbody>
</table>

**Testicular Cancer**

<table>
<thead>
<tr>
<th>Time</th>
<th>Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.45 - 17.00</td>
<td>Update on Testicular Cancer Management</td>
</tr>
<tr>
<td>17.00 - 17.15</td>
<td>Treatment for Relapse or Refractory Testicular Cancer</td>
</tr>
<tr>
<td>17.15 - 17.30</td>
<td>What to Do in Bilateral Testicular Cancer</td>
</tr>
<tr>
<td>17.30 - 17.35</td>
<td>Q&amp;A</td>
</tr>
</tbody>
</table>

WORKSHOP ON ULTRASONOGRAPHY: UROLOGY ASPECTS  
Date: November 8th, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 - 08.10</td>
<td>Opening</td>
</tr>
<tr>
<td>08.10 - 08.30</td>
<td>Ethical Consideration in Clinical Ultrasound</td>
</tr>
<tr>
<td>08.30 - 08.50</td>
<td>The Role of Ultrasound for Urologist: Focusing on the Boundaries</td>
</tr>
<tr>
<td>08.50 - 09.10</td>
<td>Abdominal-Pelvic Ultrasound: Technique &amp; Normal Sonography</td>
</tr>
<tr>
<td>09.10 - 09.30</td>
<td>Renal Ultrasound: Technique, Normal Sonography, Hydronephrosis, Hydropyonephrosis, Intrarenal Stones, Nephrocalcinosis, Hydroureter &amp; Ureter Stones</td>
</tr>
<tr>
<td>09.30 - 09.50</td>
<td>Renal Ultrasound: Cystic Lesions, Benign and Malignant Solid Lesions</td>
</tr>
<tr>
<td>09.50 - 10.10</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10.10 - 10.30</td>
<td>Scrotal Ultrasound: Indications, Examination Technique, Normal Sonography, Intra Testicular Pathology (Tumors, Infections, Torsion, etc)</td>
</tr>
<tr>
<td>10.30 - 10.50</td>
<td>Bladder and Prostate Ultrasound: Techniques, Normal Sonography, Cystitis and Bladder Stones, Prostate Hypertrophy</td>
</tr>
<tr>
<td>10.50 - 11.10</td>
<td>Transrectal Ultrasound in Prostate and Seminal Vesicles</td>
</tr>
<tr>
<td>11.10 - 11.30</td>
<td>Bladder and Prostate Ultrasound: Diverticule, Ureterocele, Benign and Malignant Tumors in the Bladder and Prostate</td>
</tr>
<tr>
<td>11.30 - 13.00</td>
<td>Lunch</td>
</tr>
<tr>
<td>13.00 - 15.00</td>
<td>Live Demonstration</td>
</tr>
<tr>
<td>15.00 - 16.30</td>
<td>Hands-on Session</td>
</tr>
<tr>
<td>16.30 - 17.00</td>
<td>Testicular Ultrasound: Extra Testicular Pathologies: Hydrocele, Varicocele, Spermatocele, etc.</td>
</tr>
</tbody>
</table>

THE ANNUAL SCIENTIFIC MEETING OF INDONESIAN UROLOGICAL ASSOCIATION (ASMIUA) 2017
## WORKSHOP ON MINIMAL INVASIVE TECHNOLOGIES ON UROLOGY

**Date**: November 8th, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 - 08.10</td>
<td>Opening Remarks</td>
</tr>
<tr>
<td>08.10 - 08.30</td>
<td>Urological Minimally Invasive Surgery Milestones in Indonesia</td>
</tr>
<tr>
<td>08.30 - 08.50</td>
<td>What’s New in Urological MIS?</td>
</tr>
<tr>
<td>08.50 - 09.10</td>
<td>Choice of Equipment and Instrument: Pneumatic/Ultrasound/Laser, Guide Wire, and Stent</td>
</tr>
<tr>
<td>09.10 - 09.30</td>
<td>Radiation Protection in Urological Procedure</td>
</tr>
<tr>
<td>09.30 - 09.40</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>09.40 - 09.50</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>09.50 - 10.10</td>
<td>PCNL Indication and Complication</td>
</tr>
<tr>
<td>10.10 - 10.30</td>
<td>PCNL Access: Xray vs Ultrasound</td>
</tr>
<tr>
<td>10.30 - 10.50</td>
<td>Method of Dilatation: Balloon, Metal, or Telescopic</td>
</tr>
<tr>
<td>10.50 - 11.10</td>
<td>Prone vs Supine PCNL: Which One is the Best?</td>
</tr>
<tr>
<td>11.10 - 11.30</td>
<td>Comparison of PCNL and mini PCNL in Management of Lower Pole Kidney Stone</td>
</tr>
<tr>
<td>11.30 - 11.40</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>11.40 - 12.30</td>
<td>Lunch</td>
</tr>
<tr>
<td>12.30 - 12.50</td>
<td>Laparoscopy</td>
</tr>
<tr>
<td>12.50 - 13.10</td>
<td>Trocar Position and Route of Access</td>
</tr>
<tr>
<td>13.10 - 13.30</td>
<td>General and Digestive Complication in Urological Laparoscopic Procedures</td>
</tr>
<tr>
<td>13.30 - 13.50</td>
<td>Laparoscopy Radical Nephrectomy: Transperitoneal or Retroperitoneal?</td>
</tr>
<tr>
<td>14.10 - 14.20</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>14.20 - 14.40</td>
<td>Indication and Complication in URS/URS</td>
</tr>
<tr>
<td>14.40 - 15.00</td>
<td>Pre Stenting: To Do or Not To Do</td>
</tr>
<tr>
<td>15.00 - 15.20</td>
<td>Use of Access Sheath in FURS: Is It Usefull to Reduce Complications?</td>
</tr>
<tr>
<td>15.20 - 15.40</td>
<td>Tips, Tricks, and Troubleshooting in FURS</td>
</tr>
<tr>
<td>15.40 - 16.00</td>
<td>PCNL vs fURS to Treat Staghorn Stone. Which One is the Best?</td>
</tr>
<tr>
<td>16.00 - 16.10</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>16.10 - 16.20</td>
<td>Coffee Break</td>
</tr>
</tbody>
</table>

### APAPU WORKSHOP

**Date**: November 8th, 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Programme</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 - 09.00</td>
<td>Opening Remarks</td>
</tr>
<tr>
<td>09.00 - 17.00</td>
<td>Hypospadias</td>
</tr>
<tr>
<td></td>
<td>Stone Surgery</td>
</tr>
<tr>
<td></td>
<td>Undescended Testis</td>
</tr>
<tr>
<td></td>
<td>Others</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>08.00 - 08.15</td>
<td>Current Classification &amp; evaluation of DSD</td>
</tr>
<tr>
<td>08.15 - 08.30</td>
<td>Genitoplasty in DSD</td>
</tr>
<tr>
<td>08.30 - 09.15</td>
<td>Panel Discussion: Current controversies in DSD management from various cultures</td>
</tr>
<tr>
<td>09.15 - 09.30</td>
<td>Tea break</td>
</tr>
<tr>
<td>09.30 - 10.00</td>
<td>Free Paper</td>
</tr>
<tr>
<td>10.00 - 10.15</td>
<td>Management of Hydronephrosis in Children: The Current Algorithm</td>
</tr>
<tr>
<td>10.15 - 10.30</td>
<td>Pyeloplasty in Children: Open, Laparoscopic, or Robotic Assisted?</td>
</tr>
<tr>
<td>10.30 - 10.45</td>
<td>Bladder Bowel Dysfunction and UTI/VUR</td>
</tr>
<tr>
<td>10.45 - 11.00</td>
<td>Continuous Antibiotic Prophylaxis in UTI: Current View</td>
</tr>
<tr>
<td>11.00 - 11.15</td>
<td>Surgical Treatment of VUR</td>
</tr>
<tr>
<td>11.15 - 11.30</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>11.30 - 13.00</td>
<td>Friday Prayer + Lunch</td>
</tr>
<tr>
<td>13.00 - 13.30</td>
<td>Free Paper</td>
</tr>
<tr>
<td>13.30 - 13.45</td>
<td>Kidney and bladder function evaluation in children with neurogenic bladder</td>
</tr>
<tr>
<td>13.45 - 14.00</td>
<td>Role of Botox in Pediatric Neurogenic Bladder</td>
</tr>
<tr>
<td>14.00 - 14.15</td>
<td>How to perform Urodynamic in Children: Tips and Tricks</td>
</tr>
<tr>
<td>14.15 - 14.30</td>
<td>Medication for neurogenic bladder</td>
</tr>
<tr>
<td>14.30 - 14.45</td>
<td>Optimization treatment of nocturnal enuresis</td>
</tr>
<tr>
<td>14.45 - 15.00</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>15.00 - 15.15</td>
<td>Tea break</td>
</tr>
<tr>
<td>15.15 - 15.30</td>
<td>Role of Adult Urologist in Pediatric Cases</td>
</tr>
<tr>
<td>15.30 - 15.45</td>
<td>Role of Bladder in Management of Lower Urinary Tract Dysfunctions</td>
</tr>
<tr>
<td>15.45 - 16.00</td>
<td>Management of Erectile Dysfunction: Current Algorithm</td>
</tr>
<tr>
<td>16.00 - 16.15</td>
<td>Strategies for Preventing and Managing Erectile Dysfunction (Invasive)</td>
</tr>
<tr>
<td>16.15 - 16.30</td>
<td>Recent Advances in the Management of BPH: Which One to Choose?</td>
</tr>
<tr>
<td>16.30 - 16.45</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>16.45 - 17.00</td>
<td>Men's Health</td>
</tr>
<tr>
<td>17.00 - 17.15</td>
<td>Lower Urinary Tract: How to Set Up and Manage it (Male)</td>
</tr>
<tr>
<td>17.15 - 17.30</td>
<td>Renal Mass: Care, biopsy when to do and impact on clinical management</td>
</tr>
<tr>
<td>17.30 - 17.45</td>
<td>State of the Art Lecture: Urolologic Oncology (Kidney)</td>
</tr>
<tr>
<td>18.00 - 20.00</td>
<td>State of the Art Lecture: Urolologic Oncology (Kidney)</td>
</tr>
<tr>
<td>20.00 - 22.00</td>
<td>Gala Dinner</td>
</tr>
<tr>
<td>22.00 - 23.00</td>
<td>State of the Art Lecture: Urolologic Oncology (Prostate)</td>
</tr>
<tr>
<td>23.00 - 23.30</td>
<td>State of the Art Lecture: Urolologic Oncology (Prostate)</td>
</tr>
<tr>
<td>23.30 - 24.00</td>
<td>State of the Art Lecture: Urolologic Oncology (Prostate)</td>
</tr>
</tbody>
</table>

**Saturday, November 11th, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00 - 09.15</td>
<td>Role of Tissue Engineering in Management of Lower Urinary Tract Dysfunctions</td>
</tr>
<tr>
<td>09.15 - 09.30</td>
<td>Panel Discussion: Current controversies in DSD management from various cultures</td>
</tr>
<tr>
<td>09.30 - 09.45</td>
<td>Laparoscopic Training: How to Set One and Impact on Residents’ Skill</td>
</tr>
<tr>
<td>09.45 - 10.00</td>
<td>Prone vs Supine Position for Percutaneous Nephrolithotripsy: Outcome and Complications</td>
</tr>
<tr>
<td>10.00 - 10.15</td>
<td>Recent Advances in the Management of BPH: Which One to Choose?</td>
</tr>
<tr>
<td>10.15 - 10.30</td>
<td>Alpha Blockers in BPH Management: Which One to Choose?</td>
</tr>
<tr>
<td>10.30 - 10.45</td>
<td>Strategies to Reduce Complications in BPH-related Surgery</td>
</tr>
<tr>
<td>10.45 - 11.00</td>
<td>Monotherapy or Combination Therapy for Treatment of LUTS due to Prostate Enlargement</td>
</tr>
<tr>
<td>11.00 - 11.15</td>
<td>Recent Advances in the Treatment of BPH</td>
</tr>
<tr>
<td>11.15 - 11.30</td>
<td>Alpha Blockers in BPH Management: Which One to Choose?</td>
</tr>
<tr>
<td>11.30 - 11.45</td>
<td>Strategies to Reduce Complications in BPH-related Surgery</td>
</tr>
<tr>
<td>11.45 - 12.00</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>12.00 - 13.00</td>
<td>Lunch</td>
</tr>
<tr>
<td>13.00 - 13.15</td>
<td>When is Chemotherapy Indicated for Hormone-naive Prostate Cancer?</td>
</tr>
<tr>
<td>13.15 - 13.30</td>
<td>Treatment for Resistant Prostate Cancer: Radical Prostatectomy</td>
</tr>
<tr>
<td>13.30 - 13.45</td>
<td>Renal Mass: Care, biopsy when to do and impact on clinical management</td>
</tr>
<tr>
<td>13.45 - 14.00</td>
<td>Strateiges for Preventing and Managing Erectile Dysfunction (Invasive)</td>
</tr>
<tr>
<td>14.00 - 14.15</td>
<td>Recent Advances in the Management of BPH: Which One to Choose?</td>
</tr>
<tr>
<td>14.15 - 14.30</td>
<td>Monotherapy or Combination Therapy for Treatment of LUTS due to Prostate Enlargement</td>
</tr>
<tr>
<td>14.30 - 14.45</td>
<td>Oral Phosphodiesterase Inhibitors Administration: Daily basis or On demand?</td>
</tr>
<tr>
<td>14.45 - 15.00</td>
<td>Sperm Retrieval Techniques: PESA, TESA, or Open Biopsy?</td>
</tr>
<tr>
<td>15.00 - 15.15</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>15.15 - 15.30</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>15.30 - 16.00</td>
<td>Closing Remarks</td>
</tr>
</tbody>
</table>
REGISTRATION & ACCOMMODATION INFORMATION

REGISTRATION BY EMAIL
To get a registration form can contact the secretariat at +62 21 7254424 or +62 21 7229339 after filling the registration form can email to erlin@gpdindonesia.com and asmiua.urology@gmail.com.

REGISTRATION BY FAX
Complete the registration form to the Secretariat Fax number at +62 21 7396261 and then reconfirm to secretariat at +62 21 7254424 or +62 21 7229339

ON SITE REGISTRATION
Those who have not registered in advance may register at onsite registration desk. Only cash payment in Rupiah will be accepted during onsite registration. No refund will be made for onsite registration fees.

REGISTRATION PAYMENT
All registration fees must be paid by bank transfer. Registrant should bear all bank charges. Please send a copy of the transaction along with the registration to the Organizing Committee.

HOTEL POLICY
Due to high demand on the hotel room at the time of congress, the congress secretariat strongly recommended early reservations.

ROOM RATE
Hotel rooms at special congress rate are being held for the congress participants at Royal Ambarrukmo Hotel Yogyakarta. Room rates are in Rupiah, per night and per room included breakfast for two persons. Reservations must be made through the congress secretariat to guarantee the indicated rate negotiates for the congress.

HOTEL RESERVATION
Hotel assignment will be made on a "FIRST COME FIRST SERVE BASIS".

REGISTRATION AND ACCOMMODATION SECRETARIAT
Department of Urology Airlangga University
School of Medicine Dr. Soetomo Hospital Surabaya
Mayjend Moestopo 6-8 Surabaya 60286, Indonesia
Phone : +62 31 5501318
Fax: +62 31 5024971
Contact : Mr. Hadi (+62 857 31333449)
Email : asmiua.urology@gmail.com

PT. GPD Indonesia
Kebalen V No. 24 A, Jakarta 12180
Phone : (+62 21) 7229339, 7254424
Fax : (+62 21) 7396261
Mobile : +62 8111 332664, +628111662664
Contact : Erlin
Email : erlin@gpdindonesia.com / gpd@gpdindonesia.com

PAYMENT BY
Bank Mandiri
Branch Surabaya Universitas Airlangga (IDR)
Acc Name : Yayasan Pengembangan Urologi Indonesia
A/C: 142 00 22505050
Swift Code: BMRIIDJA

Bank CIMB Niaga
Branch Dharmahusada Surabaya (USD)
Acc Name : Yayasan Pengembangan Urologi Indonesia
A/C : 7025 3592 9440
Swift Code : BNIADJA

HOTEL RESERVATION
Hotel assignment will be made on a “FIRST COME FIRST SERVE BASIS”.

REGISTRATION AND ACCOMMODATION SECRETARIAT
Department of Urology Airlangga University
School of Medicine Dr. Soetomo Hospital Surabaya
Mayjend Moestopo 6-8 Surabaya 60286, Indonesia
Phone : +62 31 5501318 Fax: +62 31 5024971
Contact : Mr. Hadi (+62857 31333449)
Email: asmiua.urology@gmail.com

Co-Organizer by
PT. GPD Indonesia
Kebalen V No. 24 A, Jakarta 12180
Phone : (+62 21) 7229339, 7254424
Fax : (+62 21) 7396261
Mobile : +62 8111 332664, +628111662664
Contact : Erlin
Email : erlin@gpdindonesia.com / gpd@gpdindonesia.com

DEPARTMENT OF UROLOGY AIRLANGGA UNIVERSITY
SCHOOL OF MEDICINE DR. SOETOMO HOSPITAL SURABAYA
Jl. Mayjend Moestopo 6-8 Surabaya 60286, Indonesia
Phone: +62 31 5501318 Fax: +62 31 5024971
Contact: Mr. Hadi (+62857 31333449)
Email: asmiua.urology@gmail.com

PAYMENT BY
Bank Mandiri
Branch Surabaya Universitas Airlangga (IDR)
Acc Name : Yayasan Pengembangan Urologi Indonesia
A/C: 142 00 22505050
Swift Code: BMRIIDJA

Bank CIMB Niaga
Branch Dharmahusada Surabaya (USD)
Acc Name : Yayasan Pengembangan Urologi Indonesia
A/C : 7025 3592 9440
Swift Code : BNIADJA

DEPARTMENT OF UROLOGY AIRLANGGA UNIVERSITY
SCHOOL OF MEDICINE DR. SOETOMO HOSPITAL SURABAYA
Jl. Mayjend Moestopo 6-8 Surabaya 60286, Indonesia
Phone: +62 31 5501318 Fax: +62 31 5024971
Contact: Mr. Hadi (+62857 31333449)
Email: asmiua.urology@gmail.com
CALL FOR APAPU ABSTRACTS

The 19th Annual Meeting of Asia Pacific Association of Pediatric Urology (APAPU) in conjunction with the 40th Annual Scientific Meeting of Indonesian Urological Association (ASMIUA) will be held in Jogjakarta, Indonesia on November 8th – 10th, 2017. We invite abstracts of paper on Experimental or Clinical Pediatric Urology.

Those who wish to submit are required to submit the abstract by July 1st, 2017. Please follow the instruction for abstract submission.

Deadline for Abstract Submission
Deadline for abstract submission is September 2nd, 2017 23.59 local time (Indonesia Standard Time / GMT +7)
Please submitted abstract as soon as possible to avoid internet overload.

Announcement of Accepted Abstract
The accepted abstract will be announced on September 23rd, 2017. The presenting author will be notified by email. Please note the confirmation email will not be sent to co-author(s).

Format of Presentation
- Poster
- Oral Presentation

Abstract Categories
- Oncology
- Enuresis and Non neurogenic voiding dysfunction
- Neurogenic dysfunction
- Urodynamic
- Minimal Invasive Surgery
- Stone disease
- DSD and congenital anomalies
- Reconstructive surgery, Hypo/Episipadias, Penile surgery
- VUR and UTI
- Basic science on Pediatric Urology

Abstract Acceptance
Each abstract will be reviewed by the peer reviewers. Abstract may be submitted as moderated posters or unmoderated posters.

Abstract Withdrawal
Please submit abstract withdrawal request in writing before October 2nd, 2017

PREPARATION OF ABSTRACTS
Language
Abstracts must be written and presented in English. Careful typing and proofreading is essential. Errors, misspellings, incorrect hyphenation, and deviations from the use of correct English can not be changed once the abstract is submitted.

Size
The size of the abstract is limited to 1,000 characters (including title, body of abstract, spaces).

Title
The title should clearly define the topic. Do not identify your institution in the title.

Authors
Type full family name and first name of all authors. It is advisable to check the correct spelling of the family and initials with each authors.

Body of the Abstract
- The following headings have already been for you and should not be entered in the text fields again:
  - Introduction & Objectives
  - Materials & Methods
  - Results
  - Conclusions
- If you must use other abbreviations, you must explain it the first time it appears.

Acknowledgements
Do not include references, credit, or grant support.

- Human Experimentation
  - Any human experimentation conducted as part of the submitted abstract(s) must follow the protocol approved by the institutional or local committee on ethics in human investigation.
- Abstract will be selected in moderated and non moderated. The duration of moderated abstract can have maximum time 5 minutes (3 minutes for presentation and 2 minutes for discussion)
- Submission Deadline
  - Deadline for abstract submission is September 2nd, 2017
  - Please submit your abstract by email to abstract2017.apapu@gmail.com

PREPARATION OF ABSTRACTS

Each abstract will be reviewed by the peer reviewers. Abstract may be submitted as moderated posters or unmoderated posters.

Abstract Withdrawal
Please submit abstract withdrawal request in writing before October 2nd, 2017

PREPARATION OF ABSTRACTS
Language
Abstracts must be written and presented in English. Careful typing and proofreading is essential. Errors, misspellings, incorrect hyphenation, and deviations from the use of correct English can not be changed once the abstract is submitted.

Size
The size of the abstract is limited to 1,000 characters (including title, body of abstract, spaces).

Title
The title should clearly define the topic. Do not identify your institution in the title.

Authors
Type full family name and first name of all authors. It is advisable to check the correct spelling of the family and initials with each authors.

Body of the Abstract
- The following headings have already been for you and should not be entered in the text fields again:
  - Introduction & Objectives
  - Materials & Methods
  - Results
  - Conclusions
- If you must use other abbreviations, you must explain it the first time it appears.

Acknowledgements
Do not include references, credit, or grant support.

- Human Experimentation
  - Any human experimentation conducted as part of the submitted abstract(s) must follow the protocol approved by the institutional or local committee on ethics in human investigation.
- Abstract will be selected in moderated and non moderated. The duration of moderated abstract can have maximum time 5 minutes (3 minutes for presentation and 2 minutes for discussion)
- Submission Deadline
  - Deadline for abstract submission is September 2nd, 2017
  - Please submit your abstract by email to abstract2017.apapu@gmail.com
CALL FOR ASMIUA ABSTRACTS

1. Rules for Authors
2. Preparation of Abstracts
3. Video Submissions

RULES FOR AUTHORS

Prior Publication of Material
The ASMIUA Congress is basically a forum for the presentation of novel research findings. The work covered by the abstract must not have been published (manuscript or abstract) before November 8th, 2017. If the work has been presented at another meeting, the author must disclose when and where it was presented (during submission process), so that the abstract review Committee can make its decision based on all available details.

Objectivity
The ASMIUA is committed to offer participants an open forum for scientific discussion, wherein all scientists and clinicians are invited to contribute actively. To preserve this valuable environment, the ASMIUA urges all presenters to avoid statements, symbols or other displays that are subjective and unscientific in nature.

Abstract Categories
Authors must select a category from the provided list. Paper abstract submission Categories:

- Oncology
- Functional Urology (Female and Neurourology)
- Reconstructive Surgery
- Andrological Urology
- Pediatric Urology
- Laparoscopy and Endourology
- Transplantation
- Video presentation
- Miscellaneous

Registration and Expenses
All participants must be registered for ASMIUA. Presenting authors who have not paid their registration fees will be excluded from the programme as well as from the ASMIUA proceeding book. no exceptions will be granted. all expenses such as registration, visa, airfare, lodging, etc., associated with the submission and presentation of an abstract are the responsibility of the presenter.

Failure to Present
Should the author (or a designated co-author) of an accepted abstract fail to present the work as scheduled, subsequent abstracts submitted by the individual will be flagged to the scientific committee as coming from a prior “no-show presenter”, and will be judged accordingly. This could result in the non-acceptance of future submissions at ASMIUA meetings.

Abstract Acceptance
Each abstract will be blinded and scored by three reviewers. abstracts will be accepted on the basis of scientific merit. While abstracts may be submitted as moderated posters, unmoderated posters or video presentations, the Scientific Committee reserves the right to assign final presentation categories in the Best Interest of the programme.

Abstract Revisions
Abstracts may not be revised or resubmitted after the deadline of September 30th, 2017.

Abstract withdrawal
Please submit abstract withdrawal requests in written form before October 15th, 2017.

Change of Presenting Author
Please submit requests in written form by of October 15th, 2017. after this date, changes will no longer appear in the ASMIUA Proceeding Book.

Before entering the abstract submission system you are requested to carefully read the rules regarding abstract submission:

- Abstract(s) may not have been published previously at the time of submission for the ASMIUA congress.
- Copyright of the abstract(s) is assigned to the ASMIUA and any conflicts with any other scientific association will be the sole responsibility of the author(s).
- All abstracts that are published, including figures and tables, are the property of ASMIUA and are protected by copyright.
- The Scientific Congress Office reserves the right to obtain your raw data for statistical evaluation.

PREPARATION OF ABSTRACTS

Language
Abstracts must be written and presented in English. Careful typing and proofreading is essential. The accepted abstract will be published as submitted. Errors, misspellings, incorrect hyphenation, and deviations from the use of correct English will be glaringly apparent in the published abstract. once the abstract is submitted, changes, corrections or rewording will not be possible. Presenters are requested to devote the necessary attention to language in order to avoid deviations from the use of good English. The Scientific Committee reserves the right to reject abstracts which are presented in poor English or to request an immediate revision.

Size
The submission programme will automatically calculate the size of your abstract and will not allow submissions that do not fit in the size requirements. The size of the abstract is limited to 3,000 characters (this includes title, body of abstract, spaces, tables and graphics), every picture/ graphic counts for 500 characters.

Topic
A topic has to be selected from the drop-down menu. It is important that the correct topic is selected. Please realize that topic “Unclassified and miscellaneous research” is not a real topic and should only be chosen when no other topic applies.

Title
The title should clearly define the topic. Do not identify your institution in the title. There is no minimum length for the title; however, the characters in the title are included in your total character count. The first letter of any sentence in the title will automatically begin with a capital letter. Do not type the abstract title in small letters, except for abbreviations. Do not type the entire title in capital letters.

Authors
Type full family name and first name of all authors, only omitting any titles, degrees and institutional affiliations. It is advisable to check the correct spelling of the family name and initials of each author. Please check that for authors from the same institution the name of the institution is written in the exact same way to avoid the creation of extra affiliations, which are in fact identical.

Affiliation
Type the name of the institution, Department, City and Country in English. If co-authors are from the same institution, the programme will automatically copy all information into the next boxes, so you do not have to type all information again. if co-authors are not from the same institution you can edit any box as you wish. Please make sure that the institution, department and city are written in English.

Body of the Abstract
The following headings have already been formatted for you and should not be entered in the text fields again:

- Introduction & objectives
- Materials & methods
- Results
- Conclusion

State the objective of the study, describe the material and methods, summarize the results presenting sufficient details to support the conclusions reached (it is not acceptable to state: “The results will be discussed”). Use numbers for numbers and only very well-known abbreviations. e.g., ml, kg, MRI. If you must use other abbreviations, you must explain it the first time it appears. You can use the special keys to insert tables, pictures or specific characters.
Is the event described in the case report significant?
What is the significance of the results?
Are the methods appropriate?
Is the design of the study valid?

Bear in mind that your abstract will be rated in their evaluation. Reviewers require specific data on which to base their evaluation. Several abstracts from one author may be disqualified. Statements such as “results will be discussed” will automatically disqualify the abstract.

Abstract Data
Abstracts that describe investigations of compounds that involve inadequate numbers of study subjects, or that lack quantitative data will not be accepted. Authors should not “split” data to create several abstracts from one. If splitting is judged to have occurred, priority scores of related abstracts will be reduced.

Abstracts containing identical or nearly identical data submitted from the same institution (and/or individuals) describing the same study population will be disqualified. Statements such as “results will be discussed” will automatically disqualify the abstract. Reviewers require specific data on which to base their evaluation.

Bear in mind that your abstract will be rated according to the following criteria:
• Is the design of the study valid?
• Are the methods appropriate?
• What is the significance of the results?
• Is the event described in the case report significant?

Presentation
Abstract will be selected in moderated and non moderated, by Scientific Committee of ASMIUA. The duration of moderated abstract can have maximum time 7 minutes (5 minutes for presentation and 2 minutes for discussion). All accepted moderated abstracts will be presented in poster sessions. Maximum of 14 presentations are scheduled for each poster session. Within a session standard and extended poster presentations can be placed. The criterion for the extended poster presentations is not based on higher quality piece of work, but more importantly that it requires an extensive discussion, such as controversial topics or results.

Submission Deadline
Deadline for abstract submission is September 30th, 2017. To avoid that your abstract can not be submitted due to technical difficulties, computer problems or other reasons, you are advised to submit your abstract on time. There is no possibility for late-breaking abstract submission.

Notication
In October and November 2017 abstracts will be anonymously reviewed and sessions are composed. You will receive a notification by email.

VIDEO SUBMISSION
Submission
If you select “video” as your presentation type, please upload your video via the link provided in the submission details page. Please note that videos must be uploaded prior to the submission deadline in order to be considered for review. Please indicate the ID number of the abstract in your message.

All videos must be in English and there should be a separate DVD for every abstract. One copy per video is sufficient.

Format
All videos must be in the final format, including the exact title, presenting author and production date, as accepted videos are unmoderated. Submitters may wish to include commentary, all audio and written commentary must be in English.

Duration
The video can have a maximum length of 5 minutes. Any size and formats are all accepted, but mp4 is the preferred format.

Minimal requirements for Video upload:
• Resolution PAL or NTSC (720 x 576 pixels or 720 x 420 pixel).
• Frame rate higher than 25 fps.
• Pixel aspect ratio: 4:3 or 16:9.
• Bitrate higher than 3 Mbps.
• Audio stream: mono, 44100 Hz.
• Video container: MPEG-2, MOV, WMV or AVI or any MPEG-4 encoded file.

Recommended requirements for Video upload:
• Resolution HD (1280 x 720 pixels) or higher.
• Frame rate higher than 25 fps.
• Pixel aspect 16:9.
• Bitrate higher than 6 Mbps.
• Audio stream: Stereo, 48000 Hz or better (aac, DTS, Dolby 5.1).
• Video container: MPEG-4 (MP4 or MOV).

Presentation
Videos that are accepted for presentation will be shown during the special video sessions, and all video submitted will be available during congress hours.

Deadline
The videos should be received at the ASMIUA Congress Office before September 30th, 2017. Videos received after this date will not be accepted. By accessing and/or using this system I agree (also on behalf of co-authors) to the terms of use and conditions stated above. Please note that transfer of copyright applies to all material submitted through this online system.

WE WELCOME ENTRIES TO THE BEST OF BEST ABSTRACT.

Abstract Selection
• Best poster / oral presentation
• Best video presentation

Prize will be awarded by:
• IAUI – Astellas Award for best poster
• IAUI – Cystone Award for best poster
• IAUI Award for best poster and video presentation.

If you have any questions or concerns, please contact us at scientific.asmiua2017@gmail.com
REGISTRATION FORM

THE ANNUAL SCIENTIFIC MEETING OF INDONESIAN UROLOGICAL ASSOCIATION (ASMIUA) 2017
IN CONJUNCTION WITH THE ASIA PACIFIC ASSOCIATION PEDIATRIC UROLOGIST (APAPU)

PARTICIPANT (Kindly Completed)
Title: ☐ Prof ☐ DR ☐ Dr ☐ Specialist ☐ Other
Full Name: 
Organization/Hospital/Institution: 
Country: 
Zip Code: 
Mobile Phone: 
Email: 
Sponsor: 

Please Mark (✓) on Workshop / Symposium you choose

WORKSHOP
NO | WORKSHOP | DATE | CAPACITY | REGISTRATION FEE
1 | Functional -Urodynamics | Nov 8th, 2017 | 25 pax | ☐ IDR 4,000,000 | ☐ IDR 4,500,000
2 | Urological Malignancies Chemotherapy | Nov 8th, 2017 | 25 pax | ☐ IDR 4,000,000 | ☐ IDR 4,500,000
3 | Minimal Invasive Technologies on Urology | Nov 8th, 2017 | 25 pax | ☐ IDR 3,500,000 | ☐ IDR 4,000,000
4 | Ultrasonography: Urology Aspects | Nov 8th, 2017 | 25 pax | ☐ IDR 4,000,000 | ☐ IDR 4,500,000
5 | APAPU | Nov 8th, 2017 | 25 pax | ☐ IDR 4,000,000 | ☐ IDR 4,500,000

SYMPOSIUM
NO | PARTICIPANT | LOCAL PARTICIPANT | + SEPTEMBER 15th, 2017 | + SEPTEMBER 15th, 2017
1 | Specialist / Urologist | ☐ IDR 5,000,000 | ☐ IDR 5,500,000
2 | General Practitioner | ☐ IDR 1,750,000 | ☐ IDR 2,000,000
3 | Resident | ☐ IDR 1,000,000 | ☐ IDR 1,250,000

TOTAL | IDR

SYMPOSIUM
NO | PARTICIPANT | INTERNATIONAL PARTICIPANT | + SEPTEMBER 15th, 2017 | + SEPTEMBER 15th, 2017
1 | APAPU Member | ☐ USD 650 | ☐ USD 650
2 | Non APAPU Member | ☐ USD 580 | ☐ USD 630
3 | Resident | ☐ USD 250 | ☐ USD 300

TOTAL | USD

CANCELLATION AND REFUND POLICY
Written Cancellation notice is required. Cancellation must be received before October 1st, 2017. A 50% refund will be returned after congress ended. No refund will be allowed thereafter.

PAYMENT BY
Bank Name: Bank Mandiri Branch Surabaya Universitas Airlangga (IDR)
Acc. No: 142 00 22505050
Swift Code: BMRIIDJA

Bank Name: Bank CIMB Niaga Branch Dharmahusada Surabaya (USD)
Acc. No: 7025 3592 9440
Swift Code: BNI4IDJA

Please quote the sender’s name on the bank transfer statement

SIGNATURE

This form together with the require payment and/or documentation should be emailed/faxed to:
The Congress Secretariat at GPO INDONESIA Jl. Kebalen V No. 24A Kebayoran Baru, Jakarta 12180
Tel. +6221 725 4424, +6221 7229339 | Mobile +628111332664 | Fax. +6221 7396261
Email: erlin@gpdindonesia.com / gpd@gpdindonesia.com / asmiua.urology@gmail.com

ACCOMMODATION FORM

THE ANNUAL SCIENTIFIC MEETING OF INDONESIAN UROLOGICAL ASSOCIATION (ASMIUA) 2017
IN CONJUNCTION WITH THE ASIA PACIFIC ASSOCIATION PEDIATRIC UROLOGIST (APAPU)

PARTICIPANT (Kindly Completed)
Title: ☐ Prof ☐ DR ☐ Dr ☐ Specialist ☐ Other
Full Name: 
Organization/Hospital/Institution: 
Country: 
Zip Code: 
Mobile Phone: 
Email: 
Sponsor: 

Please Mark (✓) on Hotel you choose

HOTEL | IDR/NIGHT/NETT | USD/NIGHT/NETT
Royal Ambarrukmo Yogyakarta | IDR 1,100,000 | USD 83
Grand Ambarrukmo Yogyakarta | IDR 750,000 | USD 58
The Victoria | IDR 600,000 | USD 45

CHECK – IN DATE: | CHECK – OUT DATE: | TOTAL NIGHT (S):

CHECK – IN DATE: | CHECK – OUT DATE: | TOTAL NIGHT (S):

TOTAL IDR | TOTAL USD

TERM & CONDITION
• Hotel room rate is net including 2 (two) breakfast
• Please note that official check in is 15.00 local time and check out time is 12.00 local time
• Approval of early check-in and late check-out is at discretion of the hotel.
• No reservation will be made without full deposit of nights booking due to room availability.
• Any changes and cancellations regarding to room reservation in pre-registration period must be done in writing to the Secretariat at least 168 hours prior to arrival. After the date, guaranteed payment for 1 night will be charged.
• In the event of materialization, the hotel will charge the full amount duration of stay upon check-out that causes the loss of mentioned deposit made.
• Refund may only be made after the event by bank transfer. Official letter should be submitted to Secretariat address mentioning its payer’s Bank Account.

CANCELLATION AND REFUND POLICY
Written Cancellation notice is required. Cancellation must be received before October 1st, 2017. A 50% refund will be returned after congress ended. No refund will be allowed thereafter.

PAYMENT BY
Bank Name: Bank Mandiri Branch Surabaya Universitas Airlangga (IDR)
Acc. No: 142 00 22505050
Swift Code: BMRIIDJA

Bank Name: Bank CIMB Niaga Branch Dharmahusada Surabaya (USD)
Acc. No: 7025 3592 9440
Swift Code: BNI4IDJA

Please quote the sender’s name on the bank transfer statement

SIGNATURE

This form together with the require payment and/or documentation should be emailed/faxed to:
The Congress Secretariat at GPO INDONESIA Jl. Kebalen V No. 24A Kebayoran Baru, Jakarta 12180
Tel. +6221 725 4424, +6221 7229339 | Mobile +628111332664 | Fax. +6221 7396261
Email: erlin@gpdindonesia.com / gpd@gpdindonesia.com / asmiua.urology@gmail.com